Skip to main content

Research Repository

Advanced Search

The Bristol Bladder Trial: Five year outcomes in patients treated with neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder (2023)
Journal Article
Challapalli, A., White, P., Masson, S., Foulstone, E., Renninson, E., Bravo, A., …Bahl, A. (2023). The Bristol Bladder Trial: Five year outcomes in patients treated with neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder. Journal of Clinical Oncology, 41(6_suppl), 493-493. https://doi.org/10.1200/JCO.2023.41.6_suppl.493

Background: Neoadjuvant cisplatin-based combination chemotherapy (NAC) improves survival in muscle invasive bladder cancer (MIBC). However, response rates and survival remain suboptimal. We sought to evaluate the efficacy of cabazitaxel with cisplati... Read More about The Bristol Bladder Trial: Five year outcomes in patients treated with neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder.

A single arm phase II trial of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder (2021)
Journal Article
Challapalli, A., Masson, S., White, P., Dailami, N., Pearson, S., Rowe, E., …Bahl, A. (2021). A single arm phase II trial of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder. Clinical Genitourinary Cancer, 19(4), P325-332. https://doi.org/10.1016/j.clgc.2021.02.001

Introduction: Neoadjuvant cisplatin-based combination chemotherapy improves survival in muscle-invasive bladder cancer. However, response rates and survival remain suboptimal. We evaluated the efficacy, safety, and tolerability of cisplatin plus caba... Read More about A single arm phase II trial of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder.

Pathological response rates and quality of life outcomes of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle-invasive transitional cell carcinoma of the urinary bladder (2020)
Journal Article
Challapalli, A., Masson, S., White, P., Dailami, N., Pearson, S., Rowe, E., …Bahl, A. (2020). Pathological response rates and quality of life outcomes of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle-invasive transitional cell carcinoma of the urinary bladder. Journal of Clinical Oncology, 38(15 Suppl.), 5030-5030. https://doi.org/10.1200/JCO.2020.38.15_suppl.5030